• Codexis outlined a strategy centered on its CodeEvolver enzyme-engineering platform for small-molecule pharma manufacturing and RNA production.
• RNA push targets siRNA manufacturing via its ECO Synthesis platform, including dsRNA ligase solutions and a path to GMP-scale production.
• Company reported USD 65 million in cash, cash equivalents, and investments as of 3/31/26.
• Management projected cash runway through end of 2027.
• Presentation highlighted capacity constraints in chemical siRNA synthesis, positioning ECO Synthesis as higher-throughput with lower capital intensity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Codexis Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.